DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Peramivir
Peramivir
Drug Name Peramivir Brand Name(S)
Influenza: Diagnosis and Treatment
Alpivab, INN-Peramivir
RAPIVAB (Peramivir) Injection, for Intravenous Use See the Full Prescribing Information for Drug Compatibility Information Initial U.S
Official Title: a Phase III, Randomized, Double-Blind Placebo-Controlled
Peramivir (Rapivab®) National Drug Monograph March 2015
In Vitro Activity of Favipiravir and Neuraminidase Inhibitor Combinations Against Oseltamivir-Sensitive and Oseltamivir-Resistant Pandemic Influenza a (H1N1) Virus
Q1 2018 Pharmacy & Therapeutics Committee
210854Orig1s000
Clinical Review Melisse Baylor, MD NDA 210854 Baloxavir Marboxil
Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects
Clinical Efficacy of New Neuraminidase Inhibitors, Laninamivir And
Peramivir Fact Sheet for Health Care Providers
Favipiravir in Therapy of Viral Infections
Optimizing Treatment
Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act
Peramivir Is an Intravenous Neuraminidase Inhibitor
Uses and Administration Adverse Effects Profile Profile Profile Uses
Top View
Therapeutic Class Overview Antivirals, Influenza
Potential Drug-Drug Interactions of Antiretrovirals and Antimicrobials
Antivirals Targeting the Surface Glycoproteins of Influenza Virus
Pandemic H1N1 'Swine Flu'
USP Medicare Model Guidelines V7.0 (With Example Part D Drugs)
2019 Peramivir for Influenza a and B Viral Infections
Antivirals, Influenza
An HHS Retrospective on the 2009 H1N1 Influenza Pandemic to Advance All Hazards Preparedness
Antivirals, Influenza
Review Laninamivir and Its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza
Assessment of Adverse Events Related to Anti-Influenza Neuraminidase
Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis
(H1N1) 2009 and Other Influenza Viruses
Assessment of Evidence for COVID-19-Related Treatments
Alpivab, INN-Peramivir
Influenza Antiviral Medications: Summary for Clinicians
RAPIVAB Safely and Effectively
Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal
Peramivir and Laninamivir Susceptibility of Circulating Influenza
Clinical Use of Approved Influenza Antivirals
New Treatment Strategies for Influenza Luis Del Carpio-Orantes*
RAPIVAB™ (Peramivir Injection), for Intravenous Use Syndrome and Erythema Multiforme Have Occurred with RAPIVAB
NDA 214410/Original 1 & Ndas 210854/S-04, 10; Xofluza
Influenza Antiviral Medications: Summary for Clinicians on This Page
Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects
Australian Public Assessment Report for Peramivir
Successful Treatment with Baloxavir Marboxil of a Patient with Peramivir